Related Experiment Video
Updated: Jun 22, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors
Zhao Dang1, Weihong Lai, Keduo Qian
1Surgical Science, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.
Abstract:
We previously reported that [[N-[3beta-hydroxyllup-20(29)-en-28-oyl]-7-aminoheptyl]carbamoyl]methane (A43D, 4) was a potent HIV-1 entry inhibitor. However, 4 was inactive against HIV-2 virus, suggesting the structural requirements for targeting these two retroviruses are different. In this study, a series of new betulinic acid derivatives were synthesized, and some of them displayed selective anti-HIV-2 activity at nanomolar concentrations. In comparison to compounds with anti-HIV-1 activity, a shorter C-28 side chain is required for optimal anti-HIV-2 activity.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Retrovirus Life Cycles
Subviral Agents

